Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)-Reference-Cited by-同舟云学术

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Published:2013-11-07 Issue:19 Volume:122 Page:3276-3282
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Dimopoulos Meletios A.¹,García-Sanz Ramón²,Gavriatopoulou Maria¹,Morel Pierre³,Kyrtsonis Marie-Christine⁴,Michalis Eurydiki⁵,Kartasis Zafiris⁶,Leleu Xavier⁷,Palladini Giovanni⁸,Tedeschi Alessandra⁹,Gika Dimitra¹,Merlini Giampaolo⁸,Kastritis Efstathios¹,Sonneveld Pieter¹⁰

Affiliation:

1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;

2. Hospital Universitario de Salamanca, Salamanca, Spain;

3. Hopital Schaffner, Lens, France;

4. First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;

5. Department of Hematology, Georgios Gennimatas General Hospital, Athens, Greece;

6. Department of Hematology, General Hospital of Chalkida, Chalkida, Greece;

7. Service des Maladies du Sang, Hopital Claude Huriez, Centre Hospitalier Régional Universitaire, Lille, France;

8. Amyloidosis Research and Treatment Center, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;

9. Department of Hematology, Niguarda Cà Granda Hospital, Milan, Italy; and

10. Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands

Abstract

Key Points BDR is an active regimen and induces long-lasting responses in patients with newly diagnosed WM. Induction with single-agent bortezomib may be effective in preventing complications of hyperviscosity or rituximab-induced IgM flare.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/19/3276/1370793/3276.pdf

Reference36 articles.

1. Diagnosis and management of Waldenström’s macroglobulinemia.;Dimopoulos;J Clin Oncol,2005

2. Waldenström macroglobulinemia.;Vijay;Blood,2007

3. Treatment of Waldenström’s macroglobulinemia with rituximab.;Dimopoulos;J Clin Oncol,2002

4. Extended rituximab therapy for previously untreated patients with Waldenström’s macroglobulinemia.;Dimopoulos;Clin Lymphoma,2002

5. Predictive factors for response to rituximab in Waldenström’s macroglobulinemia.;Dimopoulos;Clin Lymphoma,2005

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-07-06

2. How to manage waldenström’s macroglobulinemia in 2024;Cancer Treatment Reviews;2024-04

3. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27

4. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia;British Journal of Haematology;2024-01-29

5. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-01